National Institutes of Health

Invizyne specializes in the design of enzymes and the development of cell-free enzymatic pathways that operate independently of living cells. This innovative approach addresses many challenges associated with traditional biomanufacturing methods, which often rely on cell-based systems. By utilizing its proprietary platform, SimplePath, Invizyne aims to transform natural and renewable resources into a variety of valuable chemicals, including pharmaceuticals, fuels, materials, and food additives. The SimplePath system is designed as a modular cascade, allowing for efficient multi-step enzymatic processes. This positions Invizyne as a promising alternative to conventional chemical production methods, such as chemical synthesis and natural extraction, thus redefining the landscape of biomanufacturing.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.

Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm focuses on creating unique medicines that target the brain, utilizing cutting-edge scientific approaches and novel drug discovery techniques. In addition to its core mission, Sparian is also developing a new analgesic aimed at addressing both acute and chronic pain, further emphasizing its commitment to advancing treatments for CNS-related conditions.

Rosalind Franklin University of Medicine and Science, established in 1912, is a North Chicago, Illinois-based institution dedicated to educating future health science leaders. It comprises five schools offering degrees such as Doctor of Medicine, Doctor of Podiatric Medicine, Nurse Anesthesia, Physical Therapy, and Physician's Assistant. The university fosters research and provides opportunities for students to engage in it, both on campus and through partnerships with nearby institutions. It aims to enrich students' lives professionally, mentally, and socially through various organizations and activities. Admission requirements vary by school but generally seek students with a strong scientific background and leadership skills. The university offers financial aid to eligible students who demonstrate need.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.

Cincinnati Children’s Hospital Medical Center is a leading institution dedicated to improving child health, attracting patients and families both regionally and internationally. Recognized for its expertise, the hospital serves as a referral center for complex surgical procedures and treatments for rare pediatric diseases. The center is committed to advancing pediatric medicine by discovering innovative and effective treatment methods, solidifying its reputation as one of the foremost facilities for pediatric care globally.

AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company focuses on preclinical and toxicology services, utilizing proprietary orthotopic and metastatic tumor models. L2P Research Labs offers a range of advanced technologies, including quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans, as well as focal radiation. These capabilities allow researchers to access a complete suite of research services tailored to their needs, facilitating the advancement of scientific studies and drug development.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.

Integral Molecular, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of innovative technologies to aid drug discovery for diseases such as cancer, HIV, and arthritis. The company offers the Lipoparticle technology, which facilitates the identification and optimization of drug candidates targeting integral membrane proteins. With over 20 years of experience in the field, Integral Molecular has supported more than 400 companies in their research efforts, medication discovery, and vaccine development. Its products play a crucial role throughout the drug discovery process, particularly in the development of antibodies and chemical compounds targeting challenging protein targets.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

South Rampart Pharma is a clinical-stage life science company dedicated to developing safe and effective pain relief alternatives. The company focuses on synthesizing and characterizing new non-opioid and non-liver toxic molecules that target pain signaling pathways in the brain's periaqueductal grey (PAG) region. Its lead candidate, SRP-001, has received U.S. FDA Fast Track designation for acute pain treatment. This candidate aims to influence pain-related genes through various biological pathways, including endocannabinoid signaling and mechanical nociception, providing a promising solution to mitigate the risks associated with traditional pain medications, particularly their potential for abuse.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients with urgent unmet medical needs. The company leverages advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, to transform the traditional drug discovery process. By integrating these innovative approaches, Greenstone aims to streamline what is typically a slow and high-failure endeavor into a more rapid and efficient system, ultimately delivering safe and effective therapeutics to patients.

Spinogenix, Inc., founded in 2016 and based in San Diego, California, specializes in developing neurorestorative therapeutics aimed at addressing neurodegenerative and psychiatric diseases. The company focuses on regenerating synapses to reverse declines in cognitive and motor function, seeking to create transformative treatments for conditions characterized by synaptic loss and dysfunction. Spinogenix aims to offer innovative drugs that restore brain connections affected by neurodegenerative diseases and brain injuries. Their approach involves directly modulating synaptic proteins, with the potential for their therapeutics to be used as standalone treatments or in combination with other therapies targeting specific degenerative processes.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

The University of Utah, located in Salt Lake City, is the state's leading public university and the sole institution in Utah offering a medical school. It provides a diverse range of academic programs, featuring over 100 undergraduate majors in fields such as business, engineering, and health careers, as well as more than 90 graduate degrees. In addition to its medical school, the university also includes schools of law and pharmacy. The University of Utah promotes an active student life, hosting over 400 clubs and organizations, alongside recreational programs and cultural events. Admission to the undergraduate programs requires an application, along with academic transcripts and standardized test scores, with a minimum GPA of 2.6 and typical ACT/SAT scores around 18 and 860, respectively. Financial aid is available based on need, and students are encouraged to complete the FAFSA to determine their eligibility for various forms of assistance, including scholarships and loans.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Applied BioMath, LLC offers systems biology and pharmacology services to biotechnology and pharmaceutical companies, focusing on accelerating and de-risking drug research and development. Founded in 2013, the company specializes in developing pathway models, conducting feasibility assessments for drug targets, and performing dose projections, among other services. Their advanced mathematical modeling and simulation platform enables clients to employ quantitative decision-making strategies, improving their understanding of drug discovery processes. Additionally, Applied BioMath provides systems informatics services, including principal components analysis and Boolean logic analysis. The company has established strategic alliances with organizations such as Sanofi and Xilio Therapeutics, enhancing its capabilities and market presence. Based in Concord, Massachusetts, with additional offices in Cambridge and Oakland, Applied BioMath aims to reduce late-stage attrition in drug development through its innovative approaches and expertise.

iMetabolic Biopharma Corporation is an early-stage precision medicine drug development company dedicated to addressing obesity-related diseases. The company aims to create first-in-class therapeutics for conditions that have significant unmet medical needs. Utilizing its iPlatform technology, iMetabolic Biopharma enhances the drug discovery process, providing both economic and time-saving benefits. This innovative approach is designed to expedite the development of life-saving solutions, enabling these therapeutics to reach clinical applications more quickly and affordably.

Advent Therapeutics is a pharmaceutical company based in Lumberville, Pennsylvania, dedicated to developing therapies for micro-orphan applications, specifically targeting serious unmet medical needs in neonatal and pediatric populations. The company focuses on legacy drugs aimed at treating disorders in newborn infants, particularly those in intensive care units. By creating prenatal, neonatal, and pediatric medications, Advent Therapeutics enables healthcare professionals to provide advanced care for vulnerable patients, addressing critical gaps in existing treatment options for this underserved demographic.

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on creating and commercializing innovative anti-cancer therapies for patients with unmet medical needs. The company is advancing two late-stage therapeutics: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme and ovarian cancer, and REM-001, a photodynamic therapy aimed at cutaneous metastatic breast cancer. Kintara has established a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and sales of VAL-083 in China. Kintara Therapeutics was founded in 2009 and is headquartered in San Diego, California. The company seeks to address significant challenges faced by cancer patients who have not responded to conventional treatments.

The University of Texas MD Anderson Cancer Center is a leading institution dedicated exclusively to cancer patient care, research, education, and prevention. Located in the Texas Medical Center in Houston, Texas, it was established as one of the original three comprehensive cancer centers under the National Cancer Act of 1971. MD Anderson serves as both a degree-granting academic institution and a specialized cancer treatment facility. It is affiliated with two prominent medical schools: The University of Texas Medical School at Houston and Baylor College of Medicine. Renowned for its exceptional cancer care, MD Anderson has consistently ranked among the top cancer hospitals in the United States, earning the No. 1 position in U.S. News & World Report's "Best Hospitals" survey for ten of the past twelve years. The center is widely recognized for its commitment to advancing cancer treatment and improving patient outcomes.

The University of Utah, located in Salt Lake City, is the state's leading public university and the sole institution in Utah offering a medical school. It provides a diverse range of academic programs, featuring over 100 undergraduate majors in fields such as business, engineering, and health careers, as well as more than 90 graduate degrees. In addition to its medical school, the university also includes schools of law and pharmacy. The University of Utah promotes an active student life, hosting over 400 clubs and organizations, alongside recreational programs and cultural events. Admission to the undergraduate programs requires an application, along with academic transcripts and standardized test scores, with a minimum GPA of 2.6 and typical ACT/SAT scores around 18 and 860, respectively. Financial aid is available based on need, and students are encouraged to complete the FAFSA to determine their eligibility for various forms of assistance, including scholarships and loans.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

iQure Pharma is a global biotech company dedicated to developing innovative therapeutics for neurodegenerative diseases, particularly focusing on epilepsy. Founded by entrepreneurs and former pharmaceutical managers, the company aims to address unmet medical needs by creating new chemical entities with unique modes of action. This approach allows for the exploration of novel medical therapies, including options for patients who are resistant to existing treatments. By concentrating on these challenging conditions, iQure Pharma seeks to improve outcomes for individuals affected by epilepsy and other related disorders.

Pantherics is a new type of therapy based on modulation of peripheral GABAA receptors.

Immuto Scientific is a biotechnology services company that specializes in providing analytical insights to pharmaceutical firms involved in drug discovery. The company has developed a protein footprinting technology that automates complex protein analysis, significantly enhancing the efficiency of the drug development process for protein therapeutics. This technology offers a faster alternative to traditional methods for protein structure analysis, allowing drug developers to determine protein structures more quickly and effectively, thereby streamlining the overall drug discovery process.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that focuses on developing applications for monitoring brain health. The company has created a multi-modal brain health analytics platform that utilizes advances in artificial intelligence, neuroscience, and speech analytics to detect changes in neurological health. By leveraging proprietary metrics, Aural Analytics transforms smartphones and tablets into effective brain health monitors, capturing subtle, clinically relevant aspects of a patient's condition through speech samples. This technology enhances traditional functional rating scales used in clinical trials by providing objective, continuous outcomes, thereby allowing for more reliable evaluations of drug efficacy and other interventions. Aural Analytics' platform aims to reveal incremental changes in neurological health, facilitating accurate assessments by medical professionals.

AVM Biotechnology LLC is a clinical-stage regenerative medicine company based in Seattle, Washington. Founded in 2008, it specializes in the discovery, development, and commercialization of stem cell technologies for applications in regenerative medicine, oncology, and human biologics. The company offers a range of innovative compounds aimed at enhancing organ regeneration and immune system recovery through the modulation of stem cell binding. Its platforms include Boutique Biologics, which focuses on personalized medicine by creating patient-specific biologics that minimize immunogenicity, and Better Biologics, which enables large-scale production of human biologics that address resistance issues. AVM's lead drug, AVM0703, is an advanced formulation of dexamethasone designed to activate the body’s immune cells against cancer, autoimmunity, and infectious diseases. The company is supported by a Scientific Advisory Board comprised of experts in cancer and immunology, and it is engaged in various preclinical development projects, including small molecules and antibody-based candidates.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules aimed at treating fibrotic disorders and certain cancers, particularly triple negative breast cancer (TNBC). The company’s innovative compounds demonstrate significant efficacy in animal models for fibrosis and possess unique properties that offer cardioprotective effects in conjunction with standard chemotherapy treatments. This is especially relevant for TNBC patients who often experience delayed cardiomyopathy as a result of anthracycline treatments, which can lead to cardiovascular disease being a leading cause of death among breast cancer survivors. By co-targeting pathways involved in both cancer treatment and heart protection, NovoMedix aims to enhance patient responses to therapy while significantly reducing the risk of cardiotoxicity. The company is preparing to initiate IND enabling studies for its lead candidate, with the goal of delivering this promising therapy to TNBC patients as quickly as possible.

PostEra is a company focused on advancing drug discovery through innovative technology and strategic partnerships within the biopharma sector. Founded in 2019 and based in Santa Clara, California, PostEra provides medicinal chemistry services that combine molecular design with chemical synthesis. The company has developed algorithms that predict bioactivity and chemical reaction outcomes more effectively than traditional methods, addressing complex challenges in drug development. PostEra collaborates with major pharmaceutical companies and institutions, having secured significant funding and established multi-year partnerships with organizations such as Amgen, Pfizer, and the NIH. Additionally, the company has played a pivotal role in the COVID Moonshot initiative, which is recognized as the largest open-science drug discovery effort to date. By automating the drug development process through its machine learning platform, PostEra aims to enhance the speed, safety, and cost-effectiveness of bringing new drugs to market.

Simulations Plus is a developer of specialized software focused on Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) as well as Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation. Founded in 1996 and headquartered in Lancaster, California, the company serves various sectors, including pharmaceuticals, biotechnology, chemicals, cosmetics, and food ingredients. Its software enables pharmaceutical scientists to predict key endpoints and dynamics in silico, effectively lowering research and development costs while facilitating informed decision-making. Simulations Plus employs over 60 individuals and has a consulting team based in Buffalo, New York. The company’s technology is licensed by 19 of the top 20 pharmaceutical companies, along with a range of mid-sized and smaller firms, as well as major regulatory agencies. Additionally, trusted distributors manage sales and scientific support in Asian markets.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Delpor, Inc. is engaged in the development of innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules via a small non-mechanical subcutaneous implant. The company offers several technologies, including Prozor, which delivers antipsychotics and other small molecule drugs, and NANOPOR, designed for sustained release through specialized membrane architecture. Additionally, Delpor has developed the Delos PUMP, a self-contained device that allows for the pulsed delivery of medications at programmed intervals, benefiting treatments such as hormones for fertility, diabetes management, and pain relief. Founded in 2009 and located in San Francisco, California, Delpor aims to enhance medication adherence and patient convenience by providing an alternative to frequent injections through its implantable solutions.

4E Therapeutics is focused on developing innovative therapies for chronic pain disorders, particularly neuropathic pain, which represents a significant unmet medical need. The company specializes in creating orally bioavailable MNK inhibitors that exhibit enhanced tissue-specificity and pharmacokinetic profiles. These compounds are designed to effectively target and regulate the activity of pain-sensing neurons in the peripheral nervous system. In addition to neuropathic pain, 4E Therapeutics is also engaged in the discovery and development of treatments for migraine and acute pain, leveraging their expertise in analgesic activity demonstrated through multiple animal pain models.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Amplo Biotechnology is focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at addressing severe diseases related to the neuromuscular junction, which can lead to paralysis, breathing difficulties, and swallowing challenges. The company targets conditions such as congenital myasthenic syndromes, leveraging its lead program, AAV-Dok7, developed by a research group at the University of Tokyo. The therapies are administered through intravascular injections, initiating molecular processes that enable effective treatment for patients suffering from these rare disorders. Amplo’s mission is to create potentially curative solutions for conditions that significantly impact patient health and quality of life.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

ThermoGenesis Holdings develops and markets automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. The company offers a range of solutions for clinical biobanking, point-of-care applications, and automation in immuno-oncology. Key products include the AXP Automated Cell Separation System for isolating stem cells from umbilical cord blood, the BioArchive Automated Cryopreservation System for cryogenic storage, the PXP Point-of-Care System for processing autologous stem cells at surgical centers or clinics, and the CAR-TXpress platform for streamlining CAR-T immunotherapy manufacturing. Additionally, ThermoGenesis provides X-Series products for various cell purification tasks and the AR-TXpress Platform for large-scale cellular processing. Founded in 1986 and headquartered in Rancho Cordova, California, the company was formerly known as Cesca Therapeutics Inc.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.

ImmunoBrain Checkpoint is a biopharmaceutical company dedicated to developing innovative immunotherapies aimed at treating neurological disorders. The company's research focuses on targeting immune checkpoint pathways to create disease-modifying treatments for conditions such as Alzheimer's disease and dementia. ImmunoBrain Checkpoint's approach involves using antibodies that inhibit specific immune system molecules, which typically suppress immune activity. This inhibition facilitates a neuroprotective immunological response, potentially counteracting the effects of neurodegenerative diseases driven by proteinopathy. The foundation of their research is based on pioneering scientific discoveries made by Professor Michal Schwartz at the Weizmann Institute of Science in Israel.

Tabula Rasa Healthcare, formerly known as CareKinesis, specializes in state-of-the-art medication management solutions that leverage technology, science, and services to enhance the quality of care, reduce costs, and mitigate risks associated with ineffective medication plans. Their innovative approach aims to optimize medication therapy for improved patient outcomes.

Praxis Bioresearch is a privately-held biopharmaceutical company focused on the discovery and development of innovative prodrug stimulants aimed at treating various chronic neuropsychiatric and neurodegenerative disorders. The company's lead candidate, PRX-P4-003, is designed to provide the therapeutic benefits associated with existing stimulant medications while minimizing the risk of intravenous abuse. Through its research and development efforts, Praxis Bioresearch seeks to address unmet medical needs in the management of these complex conditions.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

AvantGen is a biotechnology company based in San Diego, established in 2006, that specializes in therapeutic antibody discovery and optimization. The company operates two divisions: Therapeutic and Research & Diagnostic. Its Therapeutic Division focuses on the discovery of novel human antibodies, antibody humanization, and affinity maturation to enhance therapeutic development. AvantGen utilizes a proprietary yeast display system and maintains a large natural human antibody database, along with fully human antibody libraries and advanced screening technologies. The company's innovative platform also includes methodologies for rabbit monoclonal antibody generation and cell engager technology. AvantGen collaborates with pharmaceutical and biotechnology firms, offering services and licensing agreements to expedite the development of antibody-based therapeutics.

CaroGen Corporation is a biopharmaceutical company based in Farmington, Connecticut, founded in 2012. It specializes in developing a novel platform technology that utilizes recombinant and replication proficient virus-like vesicles (VLVs) to create vaccines for a variety of infectious and chronic diseases. The company is advancing a portfolio of vaccine candidates with a focus on hepatitis B and hepatitis C, as well as other viral agents such as influenza and vesicular stomatitis. CaroGen's platform is designed to enhance immunotherapy by safely delivering genes for various proteins, including antigens and functional RNA molecules, which can improve treatment efficacy for both infectious diseases and cancer. The technology was developed by Professor John Rose at Yale University School of Medicine, highlighting its innovative foundation in academic research.

GenNext Technologies is a provider of instrumentation, software, and services specifically designed for structural biology researchers in the biopharmaceutical industry. The company focuses on developing protein and contract research footprinting systems, which assist pharmaceutical researchers in studying biopharmaceutical structures, interactions, folding, aggregation, and formulation. By enhancing research capabilities in structural biology, GenNext aims to accelerate biopharmaceutical development and improve therapeutic efficacy and safety. This platform enables clients to conduct advanced research within the biotechnology field, supporting their efforts to innovate and advance drug development processes.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Avexegen Therapeutics Inc. is a development-stage company based in San Diego, California, established in 2014. The company focuses on creating innovative therapies aimed at healing damaged and inflamed gut tissue in patients suffering from gastrointestinal disorders, specifically Crohn's disease and ulcerative colitis. Avexegen's approach also extends to treating premature infants affected by necrotizing enterocolitis. By developing novel treatments, the company seeks to improve long-term health outcomes for these patients, offering a promising avenue for addressing significant gastrointestinal health challenges.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coral Genomics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company specializes in optimizing drug development and deployment through the use of genomic data derived from patients. Coral Genomics focuses on creating new clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly those with autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, the company has identified a distinct population of non-responder patients and collaborates with drug developers to address their unmet medical needs.

Photonic Pharma is an early phase of drug development which uses a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company based in Farmington Hills, Michigan, dedicated to developing and commercializing therapies for various ophthalmic disorders. The company's primary focus is on innovative treatment options for front and back of the eye conditions, with its lead product candidate, Nyxol eye drops, currently in Phase 3 clinical development. Nyxol is a once-daily, preservative-free formulation aimed at addressing issues such as dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Additionally, Ocuphire is advancing another candidate, APX3330, a twice-daily oral tablet, which is entering Phase 2 clinical trials to target diabetic retinopathy and diabetic macular edema by inhibiting angiogenesis and inflammation. The company also seeks to explore opportunities for acquiring additional ophthalmic assets and forming strategic partnerships for global commercialization.

Armis Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing late-stage clinical products and antimicrobial therapies to combat antibiotic resistance and healthcare-associated infections. The company's key offerings include Ximycin, a patented localized antimicrobial therapy designed for broad-spectrum polymicrobial coverage at incision sites to prevent multi-drug resistant surgical site infections, and Veriox, a chemical platform utilizing peracid technology that provides effective treatment for infections while delivering positive effects on tissue. Armis Biopharma is dedicated to offering innovative non-systemic, non-resistant anti-infective therapeutics aimed at addressing the urgent challenges posed by resistant pathogens, with applications in the wound, orthopedic, and dermatology markets. Founded in 1997, the company is headquartered in Fort Collins, Colorado.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Lactiga is a biotherapeutics company focused on developing innovative treatments for infections, particularly for patients with Primary Immunodeficiency Diseases. By harnessing the therapeutic properties of human milk, Lactiga aims to create biologics that prevent mucosal infections associated with conditions such as selective IgA deficiency and common variable immunodeficiency. The company’s mission is to enhance the quality of life for immunodeficient and immunocompromised individuals, allowing them to lead more normal lives without relying on invasive therapies. Through its groundbreaking research, Lactiga is addressing significant health challenges posed by dangerous pathogens.

PolyCore Therapeutics is focused on developing innovative treatments for central nervous system (CNS) disorders, specifically targeting dyskinesia and cognitive impairment. The company aims to create new, affordable therapies that address the side effects associated with the treatment of Parkinson's disease and other neurological conditions. By enhancing patient mobility and quality of life, PolyCore Therapeutics seeks to contribute to more effective management of these disorders while also aiming to reduce overall healthcare costs. Their experienced team of scientists and life sciences professionals is dedicated to advancing research in this critical area of healthcare.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Plex Pharmaceuticals is a drug discovery company dedicated to transforming academic research into effective treatments for unmet medical needs, particularly in the realm of neurodegenerative disorders. The company focuses on developing modulators of heat shock proteins and FK506 Binding Protein to address conditions caused by protein misfolding, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as well as cataracts. In addition to its work in neurodegeneration, Plex is also advancing antiviral drug programs targeting diseases such as Dengue, West Nile, and Zika. Through its innovative approach, Plex aims to enhance the quality of life for patients facing complex, degenerative diseases.

ProLynx is a biotechnology company based in San Francisco, California, founded in 2009 by Daniel V. Santi and Gary W. Ashley. The company specializes in advanced linker technologies and a transformative platform designed for the controlled release of therapeutics from macromolecular conjugates. ProLynx develops systems that allow for predictable and controllable drug half-lives, addressing the challenges associated with drugs that typically have short half-lives. Their technology enables the sustained release of various therapeutic agents, including native drugs, peptides, proteins, and small molecules, from both circulating and semi-solid conjugates. This innovative approach allows clients to maintain desired drug levels over extended periods, enhancing the effectiveness of treatments.

Alpha Genesis Inc. is a provider of specific-pathogen-free nonhuman primate models and a variety of biological products for the biomedical research community. Established in 2003 and located in Yemassee, South Carolina, the company offers services that include contract research, diagnostic testing, and consultation, supporting researchers across North America, Europe, and Asia. Its full-service facility features primate housing and CDC-compliant quarantine options, ensuring the availability of nonhuman primates and biological materials necessary for effective research and development. Through its offerings, Alpha Genesis aims to facilitate advancements in biomedical sciences.